\-\ Texto\\:\\ \ \(0\)\
\-\ see\\ above\ \(10\)\
\-\ chemotherapy\\ and\\ radiation\ \(25\)\
\-\ multiple\\ bilateral\\ lesions\\ which\\ are\\ high\\ signal\\ on\\ t2\\ sequences\\,\\ low\\ signal\\ on\\ t1\\ sequences\\ and\\ with\\ minimal\\ mass\\ effect\\.\\ \\ some\\ of\\ the\\ lesions\\ reveal\\ restricted\\ diffusion\\ on\\ dwi\\ images\\.\\ \\ the\\ lesions\\ enhance\\ irregularly\\.\ \(0\)\
\-\ intravascular\\ lymphoma\\ \\(large\\ cell\\)\\ lymphoma\\,\\ of\\ the\\ b\\-cell\\ phenotype\\ \\(cd20\\ positive\\)\\.\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ septic\\ emboli\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ adem\ \(0\)\
\-\ \\â\\€\\¢\\ aggressive\\ ms\ \(0\)\
\-\ \\â\\€\\¢\\ multifocal\\ glioma\ \(0\)\
\-\ 38\\ year\\ old\\ man\\ with\\ a\\ clinical\\ diagnosis\\ of\\ ms\\.\\ \\ treated\\ with\\ high\\ dose\\ steroids\\ for\\ two\\ months\\.\\ \\ now\\ presents\\ with\\ obtundation\\,\\ visual\\ loss\\,\\ and\\ bilateral\\ extremity\\ weakness\\.\ \(0\)\
\-\ intravascular\\ lymphoma\\ is\\ also\\ called\\ angiocentric\\ lymphoma\\.\\ \\ restricted\\ diffusion\\ \\-\\ as\\ is\\ seen\\ here\\ \\-\\ is\\ typical\\ in\\ highly\\ cellular\\ lesions\\ such\\ as\\ lymphoma\\;\\ and\\,\\ this\\ finding\\ is\\ uncommon\\ in\\ multiple\\ sclerosis\\.\ \(0\)\
\-\ it\\ is\\ possible\\ that\\ the\\ clinical\\ diagnosis\\ of\\ ms\\ was\\ incorrect\\ and\\ the\\ confusing\\ mixture\\ of\\ neurologic\\ problems\\ were\\ related\\ to\\ the\\ intravascular\\ lymphoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lymphoma\\:\\ 0\\.3393761657642413\ \(0\)\
\-\ intravascular\\:\\ 0\\.3358808416197762\ \(0\)\
\-\ ms\\:\\ 0\\.27666143356659284\ \(0\)\
\-\ lesions\\:\\ 0\\.2181777972617945\ \(0\)\
\-\ restricted\\:\\ 0\\.1632634216786597\ \(0\)\
\-\ diffusion\\:\\ 0\\.1600008114862529\ \(0\)\
\-\ sequences\\:\\ 0\\.15195460049474152\ \(0\)\
\-\ angiocentric\\:\\ 0\\.15188355544910404\ \(0\)\
\-\ incorrect\\:\\ 0\\.14513284570764354\ \(0\)\
\-\ phenotype\\:\\ 0\\.13102593044994723\ \(0\)\
\-\ is\\:\\ 0\\.13004590788733825\ \(0\)\
\-\ cd20\\:\\ 0\\.12684172143852\ \(0\)\
\-\ obtundation\\:\\ 0\\.12684172143852\ \(0\)\
\-\ confusing\\:\\ 0\\.12684172143852\ \(0\)\
\-\ clinical\\:\\ 0\\.12037967994207566\ \(0\)\
\-\ the\\:\\ 0\\.11370411702104305\ \(0\)\
\-\ mixture\\:\\ 0\\.11273480618082368\ \(0\)\
\-\ cellular\\:\\ 0\\.109831944539913\ \(0\)\
\-\ cell\\:\\ 0\\.10865861643620138\ \(0\)\
\-\ high\\:\\ 0\\.10795360920629382\ \(0\)\
\-\ signal\\:\\ 0\\.10767573334379295\ \(0\)\
\-\ irregularly\\:\\ 0\\.107360855525486\ \(0\)\
\-\ bilateral\\:\\ 0\\.10208469718423996\ \(0\)\
\-\ adem\\:\\ 0\\.10200671367535098\ \(0\)\
\-\ diagnosis\\:\\ 0\\.09846734262501998\ \(0\)\
\-\ and\\:\\ 0\\.09812571864845517\ \(0\)\
\-\ emboli\\:\\ 0\\.09317212536699286\ \(0\)\
\-\ of\\:\\ 0\\.09292962278055572\ \(0\)\
\-\ multiple\\:\\ 0\\.09290736656647783\ \(0\)\
\-\ multifocal\\:\\ 0\\.09222047785553095\ \(0\)\
\-\ here\\:\\ 0\\.09046629914768797\ \(0\)\
\-\ dwi\\:\\ 0\\.09025947290027292\ \(0\)\
\-\ septic\\:\\ 0\\.09025947290027292\ \(0\)\
\-\ dose\\:\\ 0\\.08869132181276937\ \(0\)\
\-\ called\\:\\ 0\\.08869132181276937\ \(0\)\
\-\ on\\:\\ 0\\.08605102501101461\ \(0\)\
\-\ uncommon\\:\\ 0\\.08593879346239665\ \(0\)\
\-\ enhance\\:\\ 0\\.08501359440575619\ \(0\)\
\-\ highly\\:\\ 0\\.08501359440575619\ \(0\)\
\-\ 38\\:\\ 0\\.08428002647015995\ \(0\)\
\-\ steroids\\:\\ 0\\.08344038811893983\ \(0\)\
\-\ problems\\:\\ 0\\.08238293444870033\ \(0\)\
\-\ aggressive\\:\\ 0\\.08212874174313885\ \(0\)\
\-\ visual\\:\\ 0\\.0810305878285479\ \(0\)\
\-\ glioma\\:\\ 0\\.08068006332786794\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.08045041418611977\ \(0\)\
\-\ reveal\\:\\ 0\\.0798897787659551\ \(0\)\
\-\ as\\:\\ 0\\.07630857838144134\ \(0\)\
\-\ neurologic\\:\\ 0\\.07589035854166543\ \(0\)\
\-\ with\\:\\ 0\\.07438811856641855\ \(0\)\
\-\ typical\\:\\ 0\\.0733983514428818\ \(0\)\
\-\ minimal\\:\\ 0\\.07245500161352977\ \(0\)\
\-\ related\\:\\ 0\\.07217517487856444\ \(0\)\
\-\ weakness\\:\\ 0\\.06931398860061272\ \(0\)\
\-\ above\\:\\ 0\\.06851558158032628\ \(0\)\
\-\ extremity\\:\\ 0\\.06840458584383732\ \(0\)\
\-\ sclerosis\\:\\ 0\\.0676476691932731\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.06743758061630735\ \(0\)\
\-\ effect\\:\\ 0\\.06662277343868156\ \(0\)\
\-\ now\\:\\ 0\\.06519481599535576\ \(0\)\
\-\ possible\\:\\ 0\\.0643499440140024\ \(0\)\
\-\ radiation\\:\\ 0\\.06293743615132161\ \(0\)\
\-\ positive\\:\\ 0\\.062582763119783\ \(0\)\
\-\ finding\\:\\ 0\\.06242752377777227\ \(0\)\
\-\ such\\:\\ 0\\.06109189758818428\ \(0\)\
\-\ some\\:\\ 0\\.059756500425461316\ \(0\)\
\-\ t1\\:\\ 0\\.05917452393529902\ \(0\)\
\-\ treated\\:\\ 0\\.05914278074396962\ \(0\)\
\-\ see\\:\\ 0\\.05907947534903568\ \(0\)\
\-\ loss\\:\\ 0\\.05786143337345307\ \(0\)\
\-\ two\\:\\ 0\\.05640052451701741\ \(0\)\
\-\ months\\:\\ 0\\.05528235289306017\ \(0\)\
\-\ t2\\:\\ 0\\.05464096726000511\ \(0\)\
\-\ low\\:\\ 0\\.05449639935768558\ \(0\)\
\-\ metastatic\\:\\ 0\\.052088300597081715\ \(0\)\
\-\ man\\:\\ 0\\.05028023390879145\ \(0\)\
\-\ were\\:\\ 0\\.04895617657542071\ \(0\)\
\-\ it\\:\\ 0\\.04861568825086054\ \(0\)\
\-\ large\\:\\ 0\\.04758651728716228\ \(0\)\
\-\ in\\:\\ 0\\.0472527277986579\ \(0\)\
\-\ presents\\:\\ 0\\.045687231987217046\ \(0\)\
\-\ seen\\:\\ 0\\.04471282934506183\ \(0\)\
\-\ also\\:\\ 0\\.04467288698569963\ \(0\)\
\-\ images\\:\\ 0\\.043931639986320395\ \(0\)\
\-\ which\\:\\ 0\\.0431854673729924\ \(0\)\
\-\ that\\:\\ 0\\.04121500604264451\ \(0\)\
\-\ disease\\:\\ 0\\.039866567789567486\ \(0\)\
\-\ mass\\:\\ 0\\.03627740212761275\ \(0\)\
\-\ are\\:\\ 0\\.036038183948977155\ \(0\)\
\-\ was\\:\\ 0\\.0330992602012445\ \(0\)\
\-\ this\\:\\ 0\\.03263465932778058\ \(0\)\
\-\ year\\:\\ 0\\.02926901161684656\ \(0\)\
\-\ for\\:\\ 0\\.028785786938645162\ \(0\)\
\-\ old\\:\\ 0\\.02810838287197846\ \(0\)\
\-\ to\\:\\ 0\\.023743228018461904\ \(0\)\
